Abstract |
Monoclonal antibody 17-1A was administered to 25 patients with advanced unresectable carcinoma of the pancreas. Ten patients received 17-1A alone in 400 mg doses delivered intravenously, while 15 patients received 400 mg 17-1A absorbed on to autologous peripheral blood mononuclear cells collected by leukapheresis (usual yield greater than 10(9) cells). No toxicity was observed. Twenty-three patients developed circulating anti-murine immunoglobulin within three weeks of treatment, and 11 patients developed circulating anti-idiotypic immunoglobulin. Four out of 19 clinically evaluable patients (21%) showed objective regressions of tumor. Response did not correlate with the presence or absence of anti-idiotypic antibody and did not correlate with the method of treatment with 17-1A alone or 17-1A and mononuclear cells, at the time of current analysis.
|
Authors | W F Sindelar, M M Maher, D Herlyn, H F Sears, Z Steplewski, H Koprowski |
Journal | Hybridoma
(Hybridoma)
Vol. 5 Suppl 1
Pg. S125-32
(Jul 1986)
ISSN: 0272-457X [Print] United States |
PMID | 3744377
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antibodies, Monoclonal
(administration & dosage, therapeutic use, toxicity)
- Drug Administration Schedule
- Humans
- Immunotherapy
- Pancreatic Neoplasms
(therapy)
|